Business Wire

MORI-BUILDING

22.8.2019 06:02:06 CEST | Business Wire | Press release

Share
Mori Building Unveils Massive Urban Regeneration Project in Central Tokyo

Mori Building Co., Ltd., a leading urban landscape developer, has begun construction on its “Toranomon-Azabudai District Category 1 Urban Redevelopment Project,” a massive urban regeneration project aimed at revitalizing a large area of central Tokyo. A groundbreaking ceremony was held on August 5 and project completion is scheduled for the end of March 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005445/en/

The core concept of the Toranomon-Azabudai Project is that of a “Modern Urban Village,” a unique neighborhood that will combine the sophistication of a megalopolis with the intimacy of a small village in the heart of Tokyo. It will cover an area of approximately 8.1 hectares, similar to that of New York’s Rockefeller Center, and will feature extensive greenery totaling 24,000 m2 including a 6,000 m2 central square. Total floor area will be 860,400 m2 , including 213,900 m2 of office space and about 1,400 residential units. Some 20,000 office workers and 3,500 residents will work and live there, and 25-30 million people per year are expected to visit this totally new city-within-a-city.

Its physical structures will incorporate cutting-edge seismic designs and technologies, with dedicated power stations supplying electricity to the whole neighborhood. The project is designed to provide a safe city that will allow people to carry on living and working even in the event of a major disaster on the scale of the Great East Japan Earthquake. Mori Building’s unsurpassed safety and security measures are designed to create cities to escape to, rather than flee from.

Green & Wellness for enhanced lifestyles

The Toranomon-Azabudai Project will create a “unique people-centered space” by blending diverse elements and creating a world of its own. The project will seamlessly weave offices, residences, a hotel, an international school, retail shops, restaurants and cultural facilities into the fabric of everyday life, encompassing work, learning, recreation, interaction and relaxation. Built around innovative features that will include a village-like plaza surrounded by greenery, the project will create an urban space where people achieve harmony with nature as well as connecting with and inspiring each other with creativity. Far more than a mere grouping of buildings, the project will realize an integrated social ecosystem based on a people-centered approach to planning.
The core theme of the project is the huge 6,000 m2 central square offering “Green & Wellness” that will allow people from its diverse communities to gather and meet. A significant proportion of the site, including spaces on top of podium buildings, will be covered with greenery to take advantage of the stepped architecture. There will be more than two hectares of green space, including the central square, creating a seamless urban oasis filled with trees, flowers and waterscapes.

100% of the electricity supplied to the entire neighborhood will be from renewable sources, which will meet the targets stipulated in the RE100 international environmental initiative led by the UK’s Climate Group. The mental and physical wellbeing of people living and working in the area will be supported with wellness programs involving medical facilities, sports facilities, a food market, restaurants and the environment of the central square. Mori Building will apply for project certification under the WELL Building Standard™ of the International WELL Building Institute™.

A city where various aspects of people's lives will be connected seamlessly

The Toranomon-Azabudai Project will result in an urban environment where various aspects of people’s lives— working, living, relaxing, getting together, learning, playing—will be seamlessly connected. Rather than designing the city around facilities such as offices, residences and hotels, Mori Building is approaching this development from the perspective of human activity by removing the barriers between facilities. Here, various facilities will interact and collaborate, offering people the opportunity of totally new lifestyles; a place where people can spend their life in harmony with nature, where they will meet and live in a community, and where they can live creative and stimulating lives. The entire city, full of greenery, will become a place of learning, a workplace, a home, and a playground.

Leading global innovators help to implement a “Modern Urban Village” concept

The world's top creators were assembled to realize the design of this unique “Modern Urban Village,” with Mori Building playing a pivotal role in the project organization. Public realm and lower level architecture were created by Heatherwick Studio from the UK, led by Thomas Heatherwick, the designer and creator of the London 2012 Olympic Cauldron. The three skyscrapers were designed by Pelli Clarke Pelli Architects from the USA under the direction of the late César Pelli and Fred Clarke. The retail space was designed by Sou Fujimoto Architects of Japan, led by Sou Fujimoto. Other noted experts from around the world also participated.

Main participating architects, creators and designers

• Thomas Heatherwick,

Founder of Heatherwick Studio

• César Pelli (dec.)

Pelli Clarke Pelli Architects

• Fred Clarke

Pelli Clarke Pelli Architects

• Sou Fujimoto,

Sou Fujimoto Architects (Japan)

• Glenn Pushelberg and George Yabu,

Yabu Pushelberg (Canada)

• Marco Costanzi,

Marco Costanzi Architects (Italy)

• Soo K. Chan, SCDA (Singapore)

Tyler Brûlé, Winkreative (UK)

Connecting the “Hills” and creating a new cultural and economic heart of Tokyo

Mori Building’s strategic area, which incorporates the district encompassed by the Toranomon-Azabudai Project, straddles the center of Tokyo’s Minato City. The area has long had an international feel to it; many foreign-minded companies gravitate here, and it hosts a large number of foreign residents. Rich in international flavors, diversity and culture, this area has extremely high potential to become a new international hub of Tokyo.

The new project site is adjacent to Mori Building’s ARK Hills complex at the midpoint between Roppongi Hills, the “Cultural Heart of Tokyo”, and Toranomon Hills, the “Global Business Hub”. These existing Hills projects will be linked by the Toranomon-Azabudai Project; this will enhance the evolution of the entire area, creating a new international urban focal point as well as a new cultural and economic hub in the heart of Tokyo.

Project overview

Project name:

Toranomon-Azabudai District Category 1 Urban Redevelopment Project

Project executor:

Toranomon-Azabudai District Urban Redevelopment Association

Site area:

Approx. 8.1 hectares

Ground area:

Approx. 63,900 square meters

Total floor area:

Approx. 860,400 square meters

Buildings:

Residences (1,400 units), offices (approx. 213,900 m2 ), retail facilities (approx. 150 shops), hotel (approx. 120 rooms), international school (approx. 14,000 m2 ), central square (approx. 6,000 m2 ), cultural facilities (approximately 9,000 m2 )

Greenery:

Approx. 2.4 hectares

Parking:

Approx. 1,880 spaces

Project cost:

Approx. JPY 580 billion

Members:

285 rights holders (as of March, 2019)

Construction start:

August 5, 2019

Planned completion:

March 31, 2023

 

If you wish to edit the images, or you would like materials not included in these downloads (e.g. designers’ photographs) please contact Weber Shandwick Japan by email to moribldg@webershandwick.com .

Download link:(by Sep 23rd, 2019)

https://bit.ly/2TKtmUu

Password:mori20xx

About Mori Building

Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residences. The concept has been applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye